Targeting the kallikrein-related peptidases for drug development

Trends in Pharmacological Sciences

Volumn 33, Issue 12, 2012, Pages 623-634

  Sotiropoulou, Georgia ^a   Pampalakis, Georgios ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 METHYL PENTANOIC ACID [1 [(6 AMINOPYRIDIN 3 YLMETHYL)CARBAMOYL] 2 NAPHTHALEN 1 YL ETHYL]AMIDE; ANTINEOPLASTIC AGENT; APTAMER; CH 256; CH 2856; CYTOTOXIC AGENT; FE 999024; FE 9999024; ISOCOUMARIN DERIVATIVE; KALLIKREIN; KALLIKREIN 6; KALLIKREIN RELATED PEPTIDASE; KALLIKREIN RELATED PEPTIDASE 1; KALLIKREIN RELATED PEPTIDASE 10; KALLIKREIN RELATED PEPTIDASE 2; KALLIKREIN RELATED PEPTIDASE 3; KALLIKREIN RELATED PEPTIDASE 4; KALLIKREIN RELATED PEPTIDASE 5; KALLIKREIN RELATED PEPTIDASE 7; KALLIKREIN RELATED PEPTIDASE 7 INHIBITOR; KALLIKREIN RELATED PEPTIDASE 8; KALLIKREIN RELATED PEPTIDASE INHIBITOR; L 377202; MONOCLONAL ANTIBODY; PEPTIDE INHIBITOR; PRODRUG; PROTEIN INHIBITOR; PRX 302; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VA 9999024;

ALLERGY; CANCER CELL; DEGENERATIVE DISEASE; DERMATITIS; DESQUAMATION; DISEASE COURSE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; EOSINOPHILIA; EPIDERMIS; HUMAN; HYPERKERATOSIS; INFLAMMATION; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW;

ANIMALS; DRUG DESIGN; HUMANS; KALLIKREINS; MOLECULAR TARGETED THERAPY; PROTEASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 84869203481     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.09.005     Document Type: Review

References (69)

1. M.G. Lawrence Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus Endocr. Rev. 31 2010 407 446
2. G. Sotiropoulou Functional roles of human kallikrein-related peptidases J. Biol. Chem. 284 2009 32989 32994
3. H. Lilja Prostate-specific antigen and prostate cancer: prediction, detection and monitoring Nat. Rev. Cancer 8 2008 268 278
4. G. Pampalakis A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition Cancer Res. 69 2009 3779 3787
5. Y. Bando Implications of protease M/neurosin in myelination during experimental demyelination and remyelination Neurosci. Lett. 405 2006 175 180
6. S.I. Blaber Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease FASEB J. 18 2004 920 922
7. A. Iwata α-Synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies Hum. Mol. Genet. 15 2003 2625 2635
8. B. Spencer Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD Mol. Ther. 2012 10.1038/mt.2012.66
9. Charles, M.L. and Williams, M. DiaMedica Inc. Tissue kallikrein for the treatment of Parkinson's disease, US 2011/0150781 A1
10. B.K. Attwood Neuropsin cleaves EphB2 in the amygdala to control anxiety Nature 473 2011 372 375
11. S. Chavanas Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome Nat. Genet. 25 2000 141 142
12. P. Descargues Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity Nat. Genet. 37 2005 56 65
13. K. Yamasaki Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea Nat. Med. 13 2007 975 980
14. A. Eissa, and E.P. Diamandis Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions Biol. Chem. 389 2008 669 680
15. K. Oikonomopoulou Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier Biol. Chem. 391 2010 299 310
16. D. Proud The kinin system in rhinitis and asthma Clin. Rev. Allergy Immunol. 16 1998 351 364
17. N. Emami Major role of human KLK14 in seminal clot liquefaction J. Biol. Chem. 283 2008 19561 19569
18. G. Sotiropoulou, and G. Pampalakis Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation Biol. Chem. 391 2010 321 331
19. M. Evans Synthetic inhibitors of human tissue kallikrein Immunopharmacology 32 1996 117 118
20. W.C. Wolf A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness Am. J. Pathol. 159 2001 1797 1805
21. K.J. Broadley Bradykinin-induced lung inflammation and bronchoconstriction: role in parainfluenze-3 virus-induced inflammation and airway hyperreactivity J. Pharmacol. Exp. Ther. 335 2010 681 692
22. 2 antagonist-induced progression of oedematous to haemorrhagic pancreatitis in rats Br. J. Pharmacol. 155 2008 865 874
23. Evans, D.M. et al. Vantia Limited. Aminopyridine derivatives, US 2010/0076015 A1
24. P. Singh Mechanistic insights into the inhibition of prostate specific antigen by β-lactam class compounds Proteins 70 2007 1416 1428
25. A.M. LeBeau Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen Chem. Biol. 15 2008 665 674
26. A.M. LeBeau Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer Bioorg. Med. Chem. 17 2009 4888 4893
27. H. Koistinen Novel small molecule inhibitors for prostate-specific antigen Prostate 68 2008 1143 1151
28. Flohr, S. et al. Novartis Institutes for Biomedical Research Inc. Kallikrein 7 modulators, US 2010/0256144 A1
29. Linschoten, M. Use of heterocyclic compounds as SCCE inhibitors, US 2006/0258651 A1
30. G. Liang Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening Bioorg. Med. Chem. Lett. 22 2012 2450 2455
31. T.S. Teixeira Biological evaluation and docking of natural isocoumarins as inhibitors for human kallikrein 5 and 7 Bioorg. Med. Chem. Lett. 21 2011 6112 6115
32. G. Sotiropoulou Emerging interest in the kallikrein gene family for understanding and diagnosing cancer Oncol. Res. 13 2003 381 391
33. Z. Vasileiou Synthesis of the proteinase inhibitor LEKTI domain 6 by the fragment condensation method and regioselective disulfide bond formation Biopolymers 94 2010 339 349
34. Krastel, P. et al. Novartis Institutes for Biomedical Research Inc. Cyclic depsipeptides, US 2009/0156472 A1
35. S.M. Cloutier Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates Eur. J. Biochem. 271 2004 607 613
36. L.M. Felber Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14 FEBS J. 273 2006 2505 2514
37. Deperthes. D. et al. Dermadis SA. Use of serine protease inhibitors in the treatment of skin diseases, US 2011/0130338 A1
38. J.E. Swedberg Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4 Chem. Biol. 16 2009 633 643
39. D.J. Sexton Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases Biochem. J. 422 2009 383 392
40. I.A. Scarisbrick Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis Brain Pathol. 22 2012 709 722
41. S.R. Denmeade Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen Cancer Res. 58 1998 2537 2540
42. D. DeFeo-Jones A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo Nat. Med. 6 2000 1248 1252
43. R.S. DiPaola Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer J. Clin. Oncol. 20 2002 1874 1879
44. Y. Jiang Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA) Bioorg. Med. Chem. Lett. 19 2009 2587 2590
45. D. DeFeo-Jones A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo Mol. Cancer Ther. 1 2002 451 459
46. B. Elsadek Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study Eur. J. Cancer 46 2010 3434 3444
47. S.S. Chandran A prostate-specific antigen-activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer Mol. Cancer Res. 6 2007 2928 2937
48. E.A. Goun Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation Bioconjug. Chem. 17 2006 787 796
49. S.A. Williams A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease J. Natl. Cancer Inst. 99 2007 376 385
50. S.R. Denmeade Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia Eur. Urol. 59 2011 747 754
51. W. Tai Development of a peptide-drug conjugate for prostate cancer therapy Mol. Pharm. 8 2011 901 912
52. M.F. Darson Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker Urology 49 1997 857 862
53. S. Janssen Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug Prostate 66 2006 358 368
54. M. Pakkala Mimetics of the disulfide bridge between the N- and C-terminal cysteines of the KLK3-stimulating peptide B-2 Amino Acids 39 2010 233 242
55. R. Ménez Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody J. Mol. Biol. 376 2008 1021 1033
56. Santhanam, U. et al. Cosmetic uses of modified stressed yeast extracts and related compositions, US 2011/0052517 A1
57. S. Jeong Selection of RNA aptamers specific to active prostate-specific antigen Biotechnol. Lett. 32 2010 379 385
58. N. Savory Selection of DNA aptamer against prostate specific antigen using a genetic algorithm and application to sensing Biosens. Bioelectron. 26 2010 1386 1391
59. S. Arnold One round of SELEX for the generation of DNA aptamers directed against KLK6 Biol. Chem. 393 2012 343 353
60. W.L. Di Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts Mol. Ther. 19 2011 408 416
61. B. Turk Protease signaling: the cutting edge EMBO J. 31 2012 1630 1643
62. C. López-Otín, and T. Hunter The regulatory crosstalk between kinases and proteases in cancer Nat. Rev. Cancer 10 2010 278 292
63. S. El Moghrabi Tissue kallikrein permits early renal adaptation to potassium load Proc. Natl. Acad. Sci. U.S.A. 107 2010 13526 13531
64. S.A. Williams Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice Prostate 70 2010 788 796
65. J.P. Simmer Hypomaturation enamel defects in Klk4 knockout/LacZ knockin mice J. Biol. Chem. 284 2009 19110 19121
66. C. Deraison KLK5 transgenic mice reproduce NS phenotype J. Invest. Dermatol. 127 2007 S54
67. B. Klucky Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion Cancer Res. 67 2007 8198 8206
68. A. Ny, and T. Egelrud Transgenic mice over-expressing a serine protease in the skin: evidence of interferon gamma-independent MHC II expression by epidermal keratinocytes Acta Derm. Venereol. 83 2003 322 327
69. S. Shiosaka, and Y. Ishikawa Neuropsin - a possible modulator of synaptic plasticity J. Chem. Neuroanat. 42 2011 24 29